Northeast Financial Consultants’s PhaseBio Pharmaceuticals, Inc. Common Stock PHAS Stock Holding History

Northeast Financial Consultants’s Portfolio PHAS Stock Details PHAS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-37,760	Closed	-$7K	–	363
2022 Q3	$7K	Hold	37,760	–	–	﹤0.01%	333
2022 Q2	$23K	Hold	37,760	–	–	﹤0.01%	329
2022 Q1	$50K	Hold	37,760	–	–	﹤0.01%	385
2021 Q4	$99K	Buy	+37,760	New	+$114K	0.01%	349

Other funds holding PHAS

DCM

DAFNA Capital Management Los Angeles, California $440M AUM 109.12% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

HLA

Hamilton Lane Advisors Conshohocken, Pennsylvania $149M AUM 14.17% 1-Year Est. Return

IIA

IPG Investment Advisors San Diego, California $582M AUM 33.22% 1-Year Est. Return

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

Northeast Financial Consultants's PHAS Position: Q4 2022 in Review

Northeast Financial Consultants sold out of PhaseBio Pharmaceuticals, Inc. Common Stock (PHAS) in Q4 2022, closing a stake of 37,760 shares — an estimated $7K sold.

Northeast Financial Consultants first reported a position in PHAS in Q4 2021 and held it in 4 quarters. The position peaked at $99K in Q4 2021. 5 funds tracked by Wall St. Rank hold PHAS as of Q4 2022.

Northeast Financial Consultants reported no remaining PhaseBio Pharmaceuticals, Inc. Common Stock position as of Q4 2022 after selling out during the quarter.
Northeast Financial Consultants sold 37,760 PhaseBio Pharmaceuticals, Inc. Common Stock shares in Q4 2022, an estimated $7K.
Northeast Financial Consultants first reported a position in PhaseBio Pharmaceuticals, Inc. Common Stock in Q4 2021 and held it in 4 quarters.
Northeast Financial Consultants's PhaseBio Pharmaceuticals, Inc. Common Stock position peaked at $99K in Q4 2021.
5 funds tracked by Wall St. Rank held PhaseBio Pharmaceuticals, Inc. Common Stock as of Q4 2022.

Based on Northeast Financial Consultants's 13F filing for Q4 2022, filed 13 Feb 2023.